Furthermore, targeting the SIRPα-CD47 axis can attenuate vWAT-Exos-induced metabolic disorders, providing insights into the development of potential therapeutic strategies for the future treatment of obesity and metabolic disorders. Here, SIRPA is linked to obesity due to melanocortin 4 receptor deficiency.